Evidence map›Paper›PMID 34981075›Full record

ArticlemedRxiv : the preprint server for health sciences2021

SARS-CoV-2 variant exposures elicit antibody responses with differential cross-neutralization of established and emerging strains including Delta and Omicron.

Matthew T Laurie, Jamin Liu, Sara Sunshine, James Peng, Douglas Black, Anthea M Mitchell, Sabrina A Mann, Genay Pilarowski, Kelsey C Zorn, Luis Rubio and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Matthew T LaurieDepartment of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94143, USA.
Jamin LiuDepartment of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94143, USA.
Sara SunshineDepartment of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94143, USA.
James PengDepartment of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
Douglas BlackDepartment of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
Anthea M MitchellDepartment of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94143, USA.
Sabrina A MannDepartment of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94143, USA.
Genay PilarowskiThe Public Health Company, Oakland, CA 94610, USA.
Kelsey C ZornDepartment of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94143, USA.
Luis RubioDepartment of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
Sara BravoUnidos en Salud, San Francisco, CA, 94143, USA.
Carina MarquezDepartment of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
Joseph J SabatinoWeill Institute for Neurosciences, Department of Neurology, San Francisco, CA 94158, USA.
Kristen MittlWeill Institute for Neurosciences, Department of Neurology, San Francisco, CA 94158, USA.
Maya PetersenDivision of Biostatistics, University of California, Berkeley, Berkeley, CA 94720, USA.
Diane HavlirDepartment of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
Joseph DeRisiDepartment of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA 94143, USA.

Funding

San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
Identification and Characterization of the Antiviral Response to RSV Infection: A Single Cell ApproachF31AI150007 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SUNSHINE, SARA · 2020 to 2022
$116k
NIAID NIH HHS F31 AI150007NIAID NIH HHS UM1 AI069496
6 · The paper itself

Abstract

The wide spectrum of SARS-CoV-2 variants with phenotypes impacting transmission and antibody sensitivity necessitates investigation of the immune response to different spike protein versions. Here, we compare the neutralization of variants of concern, including B.1.617.2 (Delta) and B.1.1.529 (Omicron) in sera from individuals exposed to variant infection, vaccination, or both. We demonstrate that neutralizing antibody responses are strongest against variants sharing certain spike mutations with the immunizing exposure. We also observe that exposure to multiple spike variants increases the breadth of variant cross-neutralization. These findings contribute to understanding relationships between exposures and antibody responses and may inform booster vaccination strategies. SUMMARY: This study characterizes neutralization of eight different SARS-CoV-2 variants, including Delta and Omicron, with respect to nine different prior exposures, including vaccination, booster, and infections with Delta, Epsilon, and others. Different exposures were found to confer substantially differing neutralization specificity.

Identifiers

PMID34981075
PMCPMC8722618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.